Navigation Links
ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats
Date:4/14/2009

HALIFAX, April 14 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced the signing of a 3-year research agreement with Defence Research and Development Canada (DRDC). The research collaboration involves the preclinical application of IVT's DepoVax(TM) vaccine formulation to anthrax antigens to explore new methods to prevent, prepare for, and respond to biological threats.

"Dr. Les Nagata and his research team at DRDC are leaders in developing vaccines to fight deadly microbial pathogens and we look forward to this collaboration," remarked Dr. Marc Mansour, vice president of R&D at IVT. "Because our DepoVax(TM) formulation creates a long-lasting immune response and comes in a dry format that is easily reconstituted, it is well suited for the development of an effective anti-anthrax vaccine."

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Infection with anthrax is very serious, and potentially life threatening. Currently, to protect individuals who may come in contact with anthrax, immunization consists of three injections given 2 weeks apart, followed by three additional injections given at 6, 12, and 18 months. Annual booster injections of the vaccine are recommended thereafter.

ABOUT IVT

ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a privately held, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. www.immunovaccine.com.

ABOUT DRDC

DRDC is an agency of the Department of National Defence, responding to the scientific and technological needs of the Canadian Forces and national security communities. With a broad scientific program, DRDC actively collaborates with industry, international allies, academia, other government departments and the national security community. www.drdc-rddc.gc.ca.


'/>"/>
SOURCE IMMUNOVACCINE TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
3. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
4. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DUBLIN , March 30, 2017  Jazz Pharmaceuticals ... it has entered into license agreements with Nippon Shinyaku, ... Vyxeos ™ (cytarabine and daunorubicin liposome injection), or ... Under the terms of the agreements, Nippon Shinyaku will ... Vyxeos in Japan in return ...
(Date:3/29/2017)... ... March 29, 2017 , ... Zansors announced today its ... issued by the U.S. Patent & Trademark Office (USPTO). The patent covers a ... health monitoring. This invention will be critical to the future of wearable tech ...
(Date:3/29/2017)... 2017  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical ... its results for the fourth quarter and full ... marked a pivotal year for us with our ... distribution agreements, major reimbursement progress with Medicare, positive ... In addition we cleared our 2 nd ...
(Date:3/29/2017)... COLORADO SPRINGS, CO , March 29, 2017 /PRNewswire/ - Last year,s ... who support kratom are not the only efforts active to generate ... that substitute opiate based pharmaceutical drugs in the healthcare market place. ... Earlier this ... U.S. based developer and distributor of pharmaceutical and nutritional products, announced ...
Breaking Biology Technology:
(Date:3/1/2017)... March 1, 2017  Aware, Inc. (NASDAQ: AWRE), a ... Richard P. Moberg has resigned, effective March ... Chief Financial Officer and Treasurer of Aware citing a ... as a member of the Board of Directors of ... co-Chief Executive Officer and co-President, General Counsel has been ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
Breaking Biology News(10 mins):